BUZZ-EyeGate Pharmaceuticals Inc: Expands Valeant partnership

** Says it has given Valeant Pharmaceuticals International Inc commercial and manufacturing rights to the EyeGate’s drug delivery technology as well as for its experimental drug, EGP-437, for use in post-operative pain and inflammation in ocular surgery patients

** Partnership follows a 2015 agreement in which Valeant secured a license for EGP-437 to treat uveitis, a form of eye inflammation